UK meningitis outbreak: Vaccine confirmed effective against deadly strain<\/figcaption><\/figure>\n<\/div>\nHealth officials in Britain have provided an important update regarding the meningitis outbreak in southeast England. According to laboratory analysis, it has been confirmed that the outbreak is caused by a group of meningococci known as ST-41\/44\/. The Bexsero (MenB) vaccine currently administered to students has proven effective against this specific strain, providing significant reassurance to health officials. <\/p>\n
This outbreak has resulted in two deaths. As of Thursday evening, there are 18 confirmed cases and 11 more under investigation. Authorities have administered 2,360 vaccinations and about 9,840 courses of antibiotics to tackle the spread. Vaccination clinics have been expanded, although officials caution that they cannot confirm that the outbreak has been completely controlled. <\/p>\n
The outbreak has led to an increase in demand for the MenB vaccine across the UK. Major pharmacy chains including Boots have reported limited national supply due to the increase in interest. There is typically only an average of one case of invasive meningitis per day in the UK, making this group a significant public health phenomenon. <\/p>\n
Due to its rapid spread, health officials, including Deputy Chief Medical Officer Dr Thomas White, have described it as the fastest-growing outbreak in his career, linked to a “super-spreader” event at Club Chemistry in Canterbury.<\/p>\n
Meningitis vaccine coverage for infants has increased slightly over the past two years to 91%, although it remains below the 92.5% at the peak of the pandemic. Additionally, pharmacists have reported a huge increase in vaccine bookings across the UK following news of the Kent outbreak.<\/p>\n<\/p><\/div>\n